These tumor biology‐related molecular abnormalities indicate a potential for anti‐HER2 therapy other than trastuzumab, such as pertuzumab and trastuzumab emtansine (T‐DM1), and pan‐HER inhibitors afatinib and neratinib [30, 31]. This evidence concerns the gene ERBB2 and neoplasm.